

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

- 987** **Selected Articles from This Issue**

SPECIAL FEATURES

CCR Translations

- 989** **Alpelisib Efficacy without Cherry-PI3K^{WT} Mutations**
Steven Tau and Todd W. Miller
See related article, p. 1056
- 991** **New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads**
Yves Pommier and Anish Thomas
See related article, p. 1086

Reviews

- 994** **T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy**
Meredith L. Frank, Kaylene Lu, Can Erdogan, Yi Han, Jian Hu, Tao Wang, John V. Heymach, Jianjun Zhang, and Alexandre Reuben
- 1009** **Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity**
Kilian B. Kennel, Müge Bozlar, Adalbert F. De Valk, and Florian R. Greten

CLINICAL TRIALS: TARGETED THERAPY

- 1017** **A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in *BRAF* V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study**
Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, and Jayesh Desai

- 1031** **A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma**
Matthew Ingham, Shing Lee, Brian A. Van Tine, Edwin Choy, Jay Oza, Sahil Doshi, Liner Ge, Peter Oppelt, Gregory Cote, Brian Corgiat, Naomi Sender, Sarah Sta Ana, Lavan Panchalingam, Emmanuel Petricoin, and Gary K. Schwartz

- 1040** **Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial**
Jie Xu, Lu Xie, Xin Sun, Kuisheng Liu, Xin Liang, Zhenyu Cai, Xiaodong Tang, and Wei Guo

CLINICAL TRIALS: IMMUNOTHERAPY

- 1047** **Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150**
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Y. Jin, Michael L. Maitland, Martin Reck, and Mark A. Socinski

PRECISION MEDICINE AND IMAGING

- 1056** **Biology and Targetability of the Extended Spectrum of *PIK3CA* Mutations Detected in Breast Carcinoma**
Hope S. Rugo, Kira Raskina, Alexa B. Schrock, Russell W. Madison, Ryon P. Graf, Ethan S. Sokol, Smruthy Sivakumar, Jessica K. Lee, Virginia Fisher, Geoffrey R. Oxnard, and Hanna Tukachinsky
See related commentary, p. 989

- 1068** **Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: *Post Hoc* Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)**
Lee D. Cranmer, Yao Lu, Rachel S. Heise, Karla V. Ballman, Elizabeth T. Loggers, Seth M. Pollack, Michael J. Wagner, Denise K. Reinke, Patrick Schöffski, and William D. Tap

- 1077** ***ACTA2* Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer**
Sunho Park, John D. Karalis, Changjin Hong, Jean R. Clemenceau, Matthew R. Porembka, In-Ho Kim, Sung Hak Lee, Sam C. Wang, Jae-Ho Cheong, and Tae Hyun Hwang

TABLE OF CONTENTS

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

1086 **Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305**

Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, Niall J. Dickinson, Luke Masterson, Thais Cailleau, Ian Hutchinson, Balakumar Vijayakrishnan, Mary McFarlane, Kathryn Ball, Michael Davies, Arthur Lewis, Yue Huang, Anton I. Rosenbaum, Jiaqi Yuan, Jon Chesebrough, Judith Anderton, Noel Monks, Steven Novick, Jixin Wang, Nazzareno Dimasi, R. James Christie, Darrin Sabol, Frances Anne Tosto, Yann Wallez, Elisabetta Leo, Mark R. Albertella, Anna D. Staniszevska, David A. Tice, Philip W. Howard, Nadia Luheshi, and Puja Sapra

See related commentary, p. 991

1102 **Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer**

Simonetta M. Leto, Martina Ferri, Francesco Sassi, Eugenia R. Zanella, Francesca Cottino, Valentina Vurchio, Irene Catalano, Alessandro Ferrero, Caterina C. Zingaretti, Caterina Marchiò, Elena Grassi, Livio Trusolino, and Andrea Bertotti

1114 **Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality**

Shernan G. Holtan, Constanza Savid-Frontera, Kelly Walton, Anne A. Eaton, Connor Demorest, Andrea Hoeschen, Ling Zhang, Kayla Reid, Tony Kurian, Zena Sayegh, Estefania Julia, Joseph Maakaron, Veronika Bachanova, Najla El Jurdi, Margaret L. MacMillan, Daniel J. Weisdorf, Martin Felices, Jeffrey S. Miller, Bruce R. Blazar, Marco L. Davila, and Brian C. Betts

1125 **Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple *PIK3CA* Mutations**

Smruthy Sivakumar, Dexter X. Jin, Ruchita Rathod, Jeffrey Ross, Lewis C. Cantley, Maurizio Scaltriti, Jessica W. Chen, Katherine E. Hutchinson, Timothy R. Wilson, Ethan S. Sokol, and Neil Vasan

1137 **LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth**

Oihane Erice, Shruthi Narayanan, Iker Feliu, Rodrigo Entrialgo-Cadierno, Antonia Malinova, Caterina Vicentini, Elizabeth Guruceaga, Pietro Delfino, Marija Trajkovic-Arsic, Haritz Moreno, Karnele Valencia, Ester Blanco, Irati Macaya, Daniel Öhlund, Purvesh Khatri, Fernando Lecanda, Aldo Scarpa, Jens T. Siveke, Vincenzo Corbo, Mariano Ponz-Sarvis, and Silve Vicent

LETTERS TO THE EDITOR

1155 **Perioperative ctDNA-Based MRD Detection in NSCLC—Letter**

Mengxue Yu, Lingao Ju, and Xinyue Cao

1156 **Perioperative ctDNA-Based MRD Detection in NSCLC—Response**

Liang Xia, Ying Yang, Weizhi Chen, and Lunxu Liu

1157 **Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Letter**

Felipe Batalini, Lida A. Mina, and Alain Mina

1158 **Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Response**

Vincent Marmouset, Pierre-Marie Morice, Arnaud Pagès, Alexandra Leary, and Jean-Baptiste Micol

ABOUT THE COVER

The cover shows a section of gastric adenocarcinoma from a patient treated with an immune checkpoint inhibitor. Spatial transcriptomics were performed and included immunofluorescent staining for tumor cells (*green*), cancer-associated fibroblasts (*yellow*), and immune cells (*pink*). For details, see the article by Park and colleagues on page 1077 of this issue.

doi: 10.1158/1078-0432.CCR-29-6-CVR

